- Home
- LLY vs NVO Comparison
LLY vs NVO Comparison
Compare LLY & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLY | NVO |
|---|---|---|
| Founded | 1876 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | 69500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.6B | 208.2B |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | LLY | NVO |
|---|---|---|
| Price | $1,191.86 | $45.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 11 |
| Target Price | ★ $1,218.84 | $51.00 |
| AVG Volume (30 Days) | 2.0M | ★ 10.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | 0.81% | ★ 3.19% |
| EPS Growth | ★ 95.99 | N/A |
| EPS | ★ 16.19 | N/A |
| Revenue | ★ $65,179,000,000.00 | N/A |
| Revenue This Year | $27.15 | N/A |
| Revenue Next Year | $16.04 | $3.70 |
| P/E Ratio | $141.50 | ★ $13.60 |
| Revenue Growth | ★ 44.70 | N/A |
| 52 Week Low | $623.78 | $35.12 |
| 52 Week High | $1,249.45 | $64.16 |
Technical Indicators
Market Signals| Indicator | LLY | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 40.53 |
| Support Level | $1,032.70 | $42.72 |
| Resistance Level | $1,240.73 | $46.92 |
| Average True Range (ATR) | 34.58 | 1.34 |
| MACD | -3.78 | -0.75 |
| Stochastic Oscillator | 78.01 | 21.22 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.